The Use of HIFEM Technology in the Treatment of Pelvic Floor Muscles as a Cause of Female Sexual Dysfunction: A Multi-Center Pilot Study

Hlavinka TC1, Turčan P2 and Bader A3
1The Urology Place, InVita Clinics, San Antonio, USA
2Center Mediol, Olomouc, Czech Republic
3Bader Medical Institute of London, European Society of Aesthetic Gynecology ESAG, UK
Corresponding author: Pavel Turcan, Center Mediol, Olomouc, Czech Republic, Tel: 0256660255; E-mail: centrummediol@seznam.cz

Received date: November 14, 2018; Accepted date: March 2, 2019; Published date: March 9, 2019

Abstract

Introduction: Pelvic Floor Muscles (PFM) supports the pelvic floor organs, control continence and is crucial for adequate genital arousal and attainment of an orgasm. Due to the aging process, post-delivery condition or menopause, the PFM weaken. Therefore, they do not provide sufficient support to pelvic organs, bladder control, and they may negatively affect intimate satisfaction.

Aim: We aimed to investigate the High-Intensity Focused Electromagnetic (HIFEM) technology for strengthening of PFM in women with impeded sexual functioning.

Methods: 30 women (average age 36.41 ± 5.62) with limited arousal, ability to achieve orgasm and painful intercourse participated in the study. Patients underwent 6 treatments (28 minutes each) scheduled twice a week. Standardized Female Sexual Function Index (FSFI) questionnaire was used pre-, post-treatment, and at the 3-month follow-up visit. FSFI scores were statistically evaluated through student’s t-test (ɑ=0.05). Subsequently, Pearson correlation coefficient was calculated for sections arousal/lubrication, lubrication/orgasm, orgasm/satisfaction, and pain/design.

Results: The average total FSFI score significantly (p<0.001) increased from 20.06 ± 6.55 to 30.69 ± 7.55 post-treatment and to 30.29 ± 7.37 during the 3-month follow-up. A significant improvement was observed in all FSFI sections. The most significant change at the 3-month follow-up was observed in desire (76%), satisfaction (76%) and orgasm (60%) items. The overall FSFI score was improved in 93% (n=28) of patients post-treatment. All patients (n=30; 100%) showed improvement during the 3-month follow-up.

Conclusion: Our initial experience shows that HIFEM technology is a promising method in addressing women’s decreased sexual satisfaction through the strengthening of PFM.

Keywords: HIFEM; FSFI; Sexual dysfunction; Pelvic floor muscles; Myostimulation

Introduction

Healthy sexual function is an essential component of life. Sexual dysfunction can, therefore, have a negative impact on female well-being [1]. Female Sexual Dysfunction (FSD) is age-dependent and highly prevalent in premenopausal and menopausal women. Available studies report on the prevalence of sexual dysfunction in the female population to be ranging between 25% and 63% [2-9]. The incidence in women younger than 25 years was found to be approximately 20% while in women aged 55-74 years the incidence was up to 80% [7].

Pelvic floor and its functioning are closely linked to a healthy female sexual cycle. It is formed by several pelvic muscles which support the pelvic organs and maintain their normal function by keeping these organs in their anatomical position. Pelvic Floor Muscles (PFM) also play an important role in pregnancy parturition, attainment of orgasm [10-12] and are responsible for adequate genital arousal [13,14]. Firmer muscle tone adds intensity to the muscle contractions during orgasm and enables a woman to identify, isolate, and command PFM [14].

Any insult to the pelvic floor can potentially lead to denervation of the female erectile tissues followed with sexual dysfunction [10,15,16]. The main cause for the development of Pelvic Floor Disorder (PFD) occurs when the PFM and connective tissue weaken. Weak or deconditioned muscles may provide insufficient activity necessary for vaginal friction or blood flow, and thus inhibit orgasmic potential [13,14]. Therefore the initial approach for the treatment of PFD and FSD is to start with the strengthening of PFM [11,12,17].

Non-invasive addressing of PFM should be the first treatment option prior to any surgical intervention. A novel approach for non-invasive targeting of PFM is a treatment based on High-Intensity Focused Electromagnetic (HIFEM) technology. The HIFEM technology triggers intense PFM contractions by depolarizing motoneurons and inducing electric currents in the pelvic floor area. The focused electromagnetic energy penetrates into the depth of up to 10 cm into the pelvic floor area where it induces supramaximal and brain-independent contractions at high repetition rates [18,19].
Due to the intense repetitive muscle stimulation combined with the vasodilating effect of electromagnetic fields and restoration of the muscle tone, we assume that HIFEM may positively affect female intimate health and sexual functions. The subject of the study is a device based on HIFEM technology (BTL EMSELLA, BTL Industries Inc., Boston MA), which is FDA cleared for strengthening of pelvic floor muscles in the treatment of female urinary incontinence (UI).

Previous studies [18,19] investigating the HIFEM technology for UI proved that female patients reported a significant decrease in incontinence symptoms as well as a reduction in usage of incontinence pads. As the HIFEM technology impacts the PFM due to its myostimulatory effect, it could be beneficial not only in bladder control, but also in improvement of intimate life and sexual functions.

We aimed to investigate the myostimulatory effect of a High-Intensity Focused Electromagnetic (HIFEM) technology on PFM in women who reported impeded sexual functioning. We hypothesized that HIFEM can strengthen PFM and as a consequence will improve the quality of intimate life.

Method

Study design

This was a retrospective single-arm study of the patients who had been admitted to our department between 2017-2018. A total of 30 female patients (average age 36.41 ± 5.62) were enrolled. The inclusion criteria included initial impeded sexual functioning through limited arousal, impaired ability to achieve orgasm and increased intercourse pain.

Patients with pregnancy, metal implants, tumor, blood coagulation disorder, and vaginal infectious disease were excluded from the study. Before the treatments, all subjects received informed consent about the treatment procedure and signed written consent.

The patients received a treatment procedure applied to the PFM using the BTL EMSELLA device (BTL Industries Inc., Boston MA) based on HIFEM technology. The device consists of a control unit and a cable connecting the unit to a chair with an in-built circular coil. During the treatment, the device generates a focused electromagnetic field with intensities of up to 2.5 T and penetrating into depths of up to 10 cm.

The treatment protocol consisted of six treatments scheduled twice a week with a single treatment lasting for 28 minutes. The treatment protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki adopted by the General Assembly of the World Medical Association (1997-2000) and by Convention on Human Rights and Biomedicine of Council of Europe (1997).

During the treatment, patients were seated on the chair and remained fully clothed. Prior to the therapy, each of the patients received verbal instructions about the course of the therapy and about the principles of supramaximal PFM contractions. Contractions are supposed to help them to identify, isolate and command their PFM.

After the instructions, the patients were positioned on the chair and the optimal position for inducing muscle contractions was identified. Then, the therapy was initiated with low intensity which was continuously adjusted during the treatment in accordance with patient tolerance threshold [18,19].

Data collection

As a standard part of the treatment procedure, all of the 30 enrolled subjects reported patient's feedback in the form of the standardized Female Sexual Function Index (FSFI) questionnaire pre- and post-treatment, and during the 3-month follow-up visit [20]. Obtained feedback was statistically analyzed by comparing the pre- and post-intervention patients’ condition.

A normal data distribution has been assumed (0.05 significance level), therefore the parametric Student t-test was used to calculate the significance of FSFI full-scale scores and individual FSFI sections. Furthermore, Pearson correlation coefficient was calculated for paired items Arousal/Lubrication, Lubrication/Orgasm, Orgasm/Satisfaction, and Pain/Desire. Bonferroni correction was applied according to the number of the carried tests. Finally, the percentage of improved patients was calculated according to the FSFI full-scale score.

Results

The analysis of the pre-treatment FSFI questionnaires showed an average full-scale score of 20.06 ± 6.55, which according to the predefined cut-point of 26.5 indicates sexual dysfunction. The post-treatment average full-scale score significantly increased to 30.69 ± 7.55 and was maintained during 3-month follow-up at the level of 30.29 ± 7.37 (p<0.001). The total FSFI scores are shown in Figure 1.

![Figure 1: Changes in FSFI full score in treated patients. Data are visualized in box plots; blue rectangles contain 50% of data (interquartile range). Whiskers indicate the variability of the results.](Image)
observed in 28 (93%) subjects. During the follow-up appointment, all of the patients (n=30, 100%) reached a certain degree of improvement.

The improvement was observed in all individual sections of the FSFI questionnaire, while the most prominent average improvement was seen in sexual satisfaction (+76%), in sexual desire (+76%) and in orgasm (+60%). The scores of individual sections can be seen in Table 1.

### Table 1: A detailed description of FSFI items scores.

| Timing                  | Desire | Arousal | Lubrication | Orgasm | Satisfaction | Pain       |
|-------------------------|--------|---------|-------------|--------|--------------|-----------|
| Before                  | 2.79 ± 0.63 (3.00) | 3.41 ± 1.2 (3.30) | 3.42 ± 1.89 (1.60) | 3.20 ± 1.33 (3.20) | 3.01 ± 1.05 (2.80) | 4.24 ± 1.72 (4.80) |
| After                   | 4.91 ± 0.93 (5.40) | 5.24 ± 1.4 (3.70) | 4.92 ± 1.7 (6.00) | 5.13 ± 1.50 (6.00) | 5.29 ± 1.25 (5.60) | 5.20 ± 1.46 (5.60) |
| 3-Month follow-up       | 4.87 ± 0.82 (4.80) | 5.24 ± 1.4 (2.40) | 4.68 ± 1.5 (7.40) | 5.06 ± 1.48 (5.60) | 5.20 ± 1.38 (5.60) | 5.25 ± 1.48 (6.00) |

The analysis of relationships between the changes in different sections was performed to assess potential correlations. A highly significant correlation was observed in the case of before-after and before-follow-up for pairs Lubrication/Orgasm and Orgasm/Satisfaction (Table 2). The strong correlation ranged between 0.65-0.71 and was statistically significant. The correlation between the differences in Arousal and Lubrication score showed to be insignificant with weak correlation coefficients. No correlation was found between the pair Pain/Desire. Calculated correlations for investigated pairs can be found in Table 2.

### Table 2: Statistically significant (Bonferroni correction, alpha less than 0.006) correlations are marked with an asterisk symbol (*).

| Correlations               | Timeline                  | Arousal and Lubrication | Lubrication and Orgasm | Orgasm and Satisfaction | Pain and Desire |
|---------------------------|---------------------------|-------------------------|------------------------|-------------------------|-----------------|
| Difference before-after   | r=0.34                    | r=0.65*                 | r=0.68*                | r=0.13                  |                 |
| Difference before-follow-up| r=0.15                    | r=0.66*                 | r=0.71*                | r=0.03                  |                 |

### Discussion

The results suggest that the treatment procedure with HIFEM technology leads to significant improvement of the intimate life in female patients with FSD. The improvement was observed in all sections of the FSFI questionnaire in both short- and long-term results.

We contribute this improvement to well-structured intense pelvic floor workout delivered through HIFEM, induced supramaximal PFM contractions consequently accompanied with increased blood flow [21]. The correlation analysis showed a positive strong relationship between lubrication and orgasm, indicating that the treatments improved the vaginal lubrication of the patients which then was reflected in the increased ability to achieve orgasm.

Similarly, strong correlation was found between the orgasm and satisfaction. This indicates that the patients were able to reach orgasm easily which was logically reflected in their sexual satisfaction. On contrary, no correlation was found between the pain and the desire even though it could be assumed that reduced pain would lead to increased sexual desire [22,23].

The importance of PFM strength during intercourse was described by the previous authors [10-17,24-28] whose results correlate with our findings. Piassarolli et al. concluded that increased EMG activity of PFM muscles was associated with the improvement in all FSFI items [25]. Kanter et al. found that among sexually active women (n=370), a strong pelvic floor was associated with higher scores in the FSFI orgasm domain [11].

The results of our study correlate with this research as the most significant improvement was observed in sexual satisfaction, desire, and orgasm domain. Similar results were reported by Martinez et al. where women with stronger PFM scored higher in the domains: desire, excitement, orgasm and also reported higher levels of FSFI score [26]. Authors also reported a moderate correlation between PFM strength and sexual satisfaction as well as between lubrication and PFM strength. This was also supported by findings from Lowenstein et al. stating that women with strong or moderately strong PFM scored significantly higher on the FSFI orgasmic and arousal domains than women with weak PFM [27].

The duration of PFM contraction was correlated with FSFI orgasmic domain and sexual arousal. Their finding suggests that both the orgasm and arousal function are related to better PFM function. Furthermore, Aydn et al. reported that Vaginal Electrostimulation (VES) treatment leads to improvement of total FSFI score, particularly in arousal, desire, orgasm, and satisfaction sections [29]. They observed no significant changes in pain or lubrication domains. Comparing to our study, pain was the part where we observed the lowest level of improvement. However, we would like to highlight that the VES includes an intravaginal probe which is not comfortable for the patient, while the BTL Emsella procedure is performed fully clothed and without a need of intravaginal probe.
The results show the importance of PFM in female intimate life and the fact, that they can be addressed in a non-invasive way. Both sexual dysfunctions and incontinence are strongly affected by the actual condition of PFM and as such, these two indications frequently accompany each other. The treatments are ideal for improving both aspects in patients with weak pelvic muscles and are thus an alternative not only to women who experience leakage issues but also to those who feel their sexual satisfaction is impeded and could be improved.

Conclusion

The obtained FSFI data showed a significant improvement in female sexual function through the strengthening of PFM. The data suggest BTL EMSELLA as an effective tool for improving patient's sexual life satisfaction and as such, it is a promising alternative to existing treatment options and deserves further investigation.

References

1. Stephenson KR, Meston CM (2015) Why is impaired sexual function distressing to women? The primacy of pleasure in female sexual dysfunction. J Sex Med 12:728-737.
2. First MB, Wakefield JC (2013) Diagnostic criteria as dysfunction indicators: bridging the chasm between the definition of mental disorder and diagnostic criteria for specific disorders. Can J Psychiatry 58: 663-669.
3. Billups KL (2011) Sexual disabilities and sexual problems. In: Fugl-Meyer KS, editors. Sex in Sweden. Stockholm: Swedish National Institute of Health 199.
4. Hayes RD, Bennett CM, Fairley CK, Dennerstein L (2006) What can prevalence studies tell us about female sexual difficulty and dysfunction? J Sex Med 3:589-595.
5. Kontula O, Haavio-Mannila E (1916) Sexual pleasures-Enhancement of sex life in Finland 1971-1992. Acta Sociol 39: 335-337.
6. Saarinen P, Paikka M, Rosen RC (1993) Sexual dysfunction in the United States: prevalence and predictors. JAMA 258: 537-544.
7. McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, et al. (2016)Definitions of Sexual Dysfunctions in Women and Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 13:135-143.
8. Gruber B, Kline-Gruber G (1979) Female orgasm: role of pubococcygeus muscle. J Clin Psychiatry 40: 348-351.
9. Kanter G, Rogers RG, Pauls RN, Kammerer-Doak D, Thakar R (2015) A strong pelvic floor is associated with higher rates of sexual activity in women with pelvic floor disorders. Int Urogynecol J 26: 991-996.